Richard Hoglund

Head of Pharmacometrics

Clinical Pharmacology

Richard Hoglund heads the pharmacometrics group at the department of Clinical Pharmacology, MORU. He has a background in chemical engineering and pharmacology and his research is mainly focused on pharmacometrics, pharmacokinetics, pharmacodynamics and mathematical modelling in tropical medicine research, with a particular focus on antimalarial therapy.

More specific, his main research aims to optimise current and future antimalarial therapies by utilizing pharmacometric methodologies. A pharmacometric modelling approach can identify specific groups at risk of treatment failure and the derived pharmacometric models can help to evaluate and suggest new dose regimens to improve the treatment of malaria.

Recent publications

Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomised safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine and primaquine in healthy Thai adult volunteers.
Journal article

von Seidlein L. et al, (2019), Human vaccines & immunotherapeutics
Sequential open label study of the safety, tolerability and pharmacokinetic interactions between dihydroartemisinin-piperaquine and mefloquine in healthy Thai adults.
Journal article

Hanboonkunupakarn B. et al, (2019), Antimicrobial agents and chemotherapy
Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India.
Journal article

Aruldhas BW. et al, (2019), British journal of clinical pharmacology, 85, 644 - 654
Population pharmacokinetics of mefloquine given as a 3-day artesunate–mefloquine in patients with acute uncomplicated Plasmodium falciparum malaria in a multidrug-resistant area along the Thai–Myanmar border
Journal article

Hoglund RM. et al, (2018), Malaria Journal, 17
Primaquine Pharmacokinetics in Lactating Women and Breastfed Infant Exposures
Journal article

Gilder ME. et al, (2018), Clinical Infectious Diseases, 67, 1000 - 1007

More publications